Member Info for Vertizea-Sun

Yles McNulty

@MylesMcNulty

Glad to see a line drawn under this affair at #AVCT.

At least management chose not to dilute even further, but rejected all subscriptions from non-holders (which I gather was a substantial sum) to buy in the REX offer at 50p.

Approx. £42m cash in the bank now, which sees the company through to H1 2026. Hopefully another £25m+ cash to be recouped through selling the Diagnostics division over the next 12 months too, as well as any upfront cash from potential licensing deals. Besides the HCI convertible bond and outstanding options, I sincerely hope that is the last of the equity dilution before the inevitable takeover.

With everything that's happened in recent weeks, many (the majority?) may simply now not believe that Avacta's pre | CISION is as good as the company has been suggesting, e.g. "pre|CISION can change the way in which cancer is treated", "revolutionize the treatability of solid tumors", etc.

The crux of the matter is though that the AVA6000 trial has already proved beyond doubt that the platform is as good as management suggests. No MTD yet discovered. Efficacy data already emerging (which should be enough for people to understand that efficacy data will only improve, with higher / more regular doses, and when treating indications that are usually treated with anthracyclines).

Assuming a DX sale can be completed, and a first major licensing deal landed, Avacta should have sufficient cash to bring AVA6000 through to market approval for at least one indication (likely, accelerated approval for soft tissue sarcoma in the US only, after a pivotal Phase 2).

Management really needs to start pitching pre | CISION as a (superior) alternative to antibody-drug conjugates now - as that's what the investment community understands and can ascribe value to (see the plethora of multi-billion $ licensing deals and takeovers in the ADC space, over the past few years).

That Avacta is sitting here with a mkt cap of £180m (post-impending dilution), with possibly

Myles McNulty

@MylesMcNulty

·

Feb 28

Absolutely sickened by this placing by

@avacta

. Raising up to £26.8m at 50p.

This will not be forgotten, nor forgiven. Fundamental changes must be made at #AVCT.

Remember: we retail shareholders hold almost 90% of the stock. We collectively hold the power over who runs our…

Show more

Someone explain why putting AVA6000 in the hands of BP speeds up licensing? What can they do for the FDA Avacta can't?

Would SB and CC have joined with crap C7 data. Not to mention Shaun Chilton.

More Took rubbish.

Fingers crossed AS has better things to do than deal with silly rumours. I'm not expecting news until AACR.

Excellent article. Thank you.

Takeda owns about 30K shares in Avacta.....or it did a couple of years ago. No one ever explained why the Japanese company took that interest a good few years ago....and left it untouched. It's a relatively small amount and in itself quite irrelevant. Odd.

Absolutely. BV is not wrong to bang on about this.

Madness of crowds. "FIRE" was shouted in a crowded theatre.....that was all.

Exactly hunky, exactly.

Thank you gmcc for today's most useful information. I've always thought it hilarious the suggestion AS would wrap Launch into Diagnostics and sell something he's only just bloody well bought.

It's a popular trading share with lots of liquidity and now grossly undervalued.....compared to the 70 AIM companies worth more. Even Lok'N Store has a higher M'Cap.

March 5th is submission of Abstract.....TITLE

April 5th is submission of Abstract.....TEXT

And cut-off date of 5th April for Text of Abstract.

TwiX is saying cut-off date March 5th for Title of Abstract.

Daewoo are very, very confident that Avacta's Affimers can deliver. And we are due an update on the revaluation of the JV.....Affyxell.

Who wouldn't want to be associated with tomorrow's triumph. Another tick-up.

"it would be very easy to let something slip that he shouldn't.'"

chance would be a fine thing.

"The London stock market’s decline is starting to look terminal"

https://www.telegraph.co.uk/business/2024/02/08/london-stock-markets-decline-starting-look-terminal/

19 Jan 2024:

Dr Christina Coughlin, commented:

"I am thrilled to join the team during such a pivotal time for the company as we move our game-changing pipeline forward for the benefit of patients."

I wonder If Charles is being treated with "affordable" chemo or eye wateringly expensive immunotherapy? Two years ago my own sibling benefitted from it and we were told the cost was the same as a small house. Above all else AVA6000 appears to be a very practical medicine.